Search

Cevimeline

Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.

Autologous cultured chondrocytes

It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.

(+)-menthol

Flosequinan

Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]

Pariglasgene brecaparvovec

continued approval potentially contingent on confirmatory trials. … [L64050] Restoring hepatic G6Pase activity supports the release of glucose during fasting, and in clinical studies reduced patients' reliance on dietary cornstarch used to prevent hypoglycemia.

Binimetinib

[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients … with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.

Enprofylline

Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. … Long-term enprofylline administration may be associated with elevation in liver enzyme levels and unpredictable blood levels.

Artemether

Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. … </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

Vanzacaftor

[L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor … It is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.

Tranylcypromine

An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine). … It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311).